Literature DB >> 30072063

Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults.

Floris P Barthel1, Kevin C Johnson2, Pieter Wesseling3, Roel G W Verhaak4.   

Abstract

Recent advances in molecular analysis and genome sequencing have prompted a paradigm shift in neuropathology. This article discusses the discovery and clinical relevance of molecular biomarkers in diffuse gliomas in adults and how these biomarkers led to revision of the World Health Organization classification of these tumors. We relate progress in clinical classification to an overview of studies using molecular profiling to study gene expression and DNA methylation to categorize diffuse gliomas in adults and issues dealing with intratumoral heterogeneity. These efforts will refine the taxonomy of diffuse gliomas, facilitate selection of appropriate treatment regimens, and ultimately improve patient's lives.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  1p/19q codeletion; Astrocytoma; Diffuse gliomas; IDH mutations; Oligodendroglioma

Mesh:

Year:  2018        PMID: 30072063      PMCID: PMC6322909          DOI: 10.1016/j.ncl.2018.04.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  111 in total

1.  Microchemical Color Reactions as an Aid to the Identification and Classification of Brain Tumors.

Authors:  P Bailey; H Cushing
Journal:  Proc Natl Acad Sci U S A       Date:  1925-01       Impact factor: 11.205

2.  Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study.

Authors:  K Aldape; M L Simmons; R L Davis; R Miike; J Wiencke; G Barger; M Lee; P Chen; M Wrensch
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

3.  A CRITICAL REVIEW: THE PATHOLOGY OF CEREBRAL GLIOMAS.

Authors:  H J Scherer
Journal:  J Neurol Psychiatry       Date:  1940-04

Review 4.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

5.  Systematic analysis of telomere length and somatic alterations in 31 cancer types.

Authors:  Floris P Barthel; Wei Wei; Ming Tang; Emmanuel Martinez-Ledesma; Xin Hu; Samirkumar B Amin; Kadir C Akdemir; Sahil Seth; Xingzhi Song; Qianghu Wang; Tara Lichtenberg; Jian Hu; Jianhua Zhang; Siyuan Zheng; Roel G W Verhaak
Journal:  Nat Genet       Date:  2017-01-30       Impact factor: 38.330

6.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.

Authors:  M Esteller; S R Hamilton; P C Burger; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

Review 7.  Epigenetic plasticity and the hallmarks of cancer.

Authors:  William A Flavahan; Elizabeth Gaskell; Bradley E Bernstein
Journal:  Science       Date:  2017-07-21       Impact factor: 47.728

8.  Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma.

Authors:  Annalisa R Stone; William Bobo; Daniel J Brat; Nara S Devi; Erwin G Van Meir; Paula M Vertino
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

9.  Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.

Authors:  Johan M Kros; Thierry Gorlia; Mathilde C Kouwenhoven; Ping-Pin Zheng; V Peter Collins; Dominique Figarella-Branger; Felice Giangaspero; Caterina Giannini; Karima Mokhtari; Sverre J Mørk; Anders Paetau; Guido Reifenberger; Martin J van den Bent
Journal:  J Neuropathol Exp Neurol       Date:  2007-06       Impact factor: 3.685

10.  The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space.

Authors:  Johanna Klughammer; Barbara Kiesel; Thomas Roetzer; Nikolaus Fortelny; Amelie Nemc; Karl-Heinz Nenning; Julia Furtner; Nathan C Sheffield; Paul Datlinger; Nadine Peter; Martha Nowosielski; Marco Augustin; Mario Mischkulnig; Thomas Ströbel; Donat Alpar; Bekir Ergüner; Martin Senekowitsch; Patrizia Moser; Christian F Freyschlag; Johannes Kerschbaumer; Claudius Thomé; Astrid E Grams; Günther Stockhammer; Melitta Kitzwoegerer; Stefan Oberndorfer; Franz Marhold; Serge Weis; Johannes Trenkler; Johanna Buchroithner; Josef Pichler; Johannes Haybaeck; Stefanie Krassnig; Kariem Mahdy Ali; Gord von Campe; Franz Payer; Camillo Sherif; Julius Preiser; Thomas Hauser; Peter A Winkler; Waltraud Kleindienst; Franz Würtz; Tanisa Brandner-Kokalj; Martin Stultschnig; Stefan Schweiger; Karin Dieckmann; Matthias Preusser; Georg Langs; Bernhard Baumann; Engelbert Knosp; Georg Widhalm; Christine Marosi; Johannes A Hainfellner; Adelheid Woehrer; Christoph Bock
Journal:  Nat Med       Date:  2018-08-27       Impact factor: 53.440

View more
  4 in total

1.  MethylSPWNet and MethylCapsNet: Biologically Motivated Organization of DNAm Neural Networks, Inspired by Capsule Networks.

Authors:  Joshua J Levy; Youdinghuan Chen; Nasim Azizgolshani; Curtis L Petersen; Alexander J Titus; Erika L Moen; Louis J Vaickus; Lucas A Salas; Brock C Christensen
Journal:  NPJ Syst Biol Appl       Date:  2021-08-20

2.  Integrated analysis of 34 microarray datasets reveals CBX3 as a diagnostic and prognostic biomarker in glioblastoma.

Authors:  Siqi Wang; Fang Liu; Yuhui Wang; Wenliang Fan; Hongyang Zhao; Liying Liu; Chunyuan Cen; Xiaobin Jiang; Min Sun; Ping Han
Journal:  J Transl Med       Date:  2019-05-28       Impact factor: 5.531

3.  The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas.

Authors:  Shujun Liu; Yadi Zhu; Chenxi Zhang; Xiangrui Meng; Bo Sun; Guojun Zhang; Yubo Fan; Xixiong Kang
Journal:  Front Oncol       Date:  2020-01-23       Impact factor: 6.244

Review 4.  System-based approaches as prognostic tools for glioblastoma.

Authors:  Manuela Salvucci; Zaitun Zakaria; Steven Carberry; Amanda Tivnan; Volker Seifert; Donat Kögel; Brona M Murphy; Jochen H M Prehn
Journal:  BMC Cancer       Date:  2019-11-12       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.